Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones by Clerico, Aldo et al.
doi:10.1152/ajpheart.00226.2011
 301:H12-H20, 2011. First published 6 May 2011;Am J Physiol Heart Circ Physiol
Aldo Clerico, Alberto Giannoni, Simona Vittorini and Claudio Passino
natriuretic hormones
physiological role and clinical utility of cardiac 
Thirty years of the heart as an endocrine organ:
You might find this additional info useful...
106 articles, 41 of which can be accessed free at:This article cites 
 http://ajpheart.physiology.org/content/301/1/H12.full.html#ref-list-1
including high resolution figures, can be found at:Updated information and services 
 http://ajpheart.physiology.org/content/301/1/H12.full.html
 can be found at:AJP - Heart and Circulatory Physiologyabout Additional material and information 
http://www.the-aps.org/publications/ajpheart
This infomation is current as of July 13, 2011.
 
ISSN: 0363-6135, ESSN: 1522-1539. Visit our website at http://www.the-aps.org/.
Physiological Society, 9650 Rockville Pike, Bethesda MD 20814-3991. Copyright © 2011 by the American Physiological Society. 
intact animal to the cellular, subcellular, and molecular levels. It is published 12 times a year (monthly) by the American
lymphatics, including experimental and theoretical studies of cardiovascular function at all levels of organization ranging from the 
 publishes original investigations on the physiology of the heart, blood vessels, andAJP - Heart and Circulatory Physiology
 o
n
 July 13, 2011
ajpheart.physiology.org
D
ow
nloaded from
 
Thirty years of the heart as an endocrine organ: physiological role
and clinical utility of cardiac natriuretic hormones
Aldo Clerico, Alberto Giannoni, Simona Vittorini, and Claudio Passino
Scuola Superiore Sant’Anna, Fondazione del Consiglio Nazionale delle Ricerche e della Regione Toscana, Gabriele
Monasterio, Pisa, Italy
Submitted 7 March 2011; accepted in final form 4 May 2011
Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as an
endocrine organ: physiological role and clinical utility of cardiac natriuretic
hormones. Am J Physiol Heart Circ Physiol 301: H12–H20, 2011. First published
May 6, 2011; doi:10.1152/ajpheart.00226.2011.—Thirty years ago, De Bold et al.
(20) reported that atrial extracts contain some biologically active peptides, which
promote a rapid and massive diuresis and natriuresis when injected in rats. It is now
clear that the heart also exerts an endocrine function and in this way plays a key role
in the regulation of cardiovascular and renal systems. The aim of this review is to
discuss some recent insights and still-debated findings regarding the cardiac
natriuretic hormones (CNHs) produced and secreted by cardiomyocytes (i.e., atrial
natriuretic peptide and B-type natriuretic peptide). The functional status of the CNH
system depends not only on the production/secretion of CNHs by cardiomyocytes
but also on both the peripheral activation of circulating inactive precursor of
natriuretic hormones and the transduction of the hormone signal by specific
receptors. In this review, we will discuss the data supporting the hypothesis that the
production and secretion of CNHs is the result of a complex integration among
mechanical, chemical, hemodynamic, humoral, ischemic, and inflammatory inputs.
The cross talk among endocrine function, adipose tissue, and sex steroid hormones
will be discussed more in detail, considering the clinically relevant relationships
linking together cardiovascular risk, sex, and body fat development and distribu-
tion. Finally, we will review the pathophysiological role and the clinical relevance
of both peripheral maturation of the precursor of B-type natriuretic peptides and
hormone signal transduction.
B-type natriuretic peptide; sex steroids; adipokines; heart failure; cardiovascular
risk
THIRTY YEARS AGO, De Bold et al. (20) reported that atrial
extracts contain some biological active peptides, which pro-
mote a rapid and massive diuresis and natriuresis when injected
in rats. Several endogenous peptide hormones with natriuretic
and vasodilator activity have been identified in the human
blood and peripheral tissues (3, 30, 69, 85, 86). Atrial natri-
uretic peptide (ANP), brain natriuretic peptide (BNP), and their
related peptides are predominantly produced by atrial and
ventricular cardiomyocytes. The term “cardiac natriuretic hor-
mones” (CNHs) will be used in this review to indicate these
two families of natriuretic peptides. Another natriuretic pep-
tide, named C-type natriuretic peptide (CNP), is predominantly
produced by the endothelial cells, including those of cardiac
vessels. Finally, urodilatin is an NH2-terminal (NT) 4-amino
acid (aa) extented form of ANP, which is produced by the same
ANP gene and secreted into the urine by renal tubular cells (16,
34, 69).
From the original observations made 30 years ago, the
advances in this particular research field have determined a
complete revision about the role of the heart. It is now clear
that the heart also exerts an endocrine function and in this way
plays a key role in the regulation of cardiovascular and renal
function. The aim of this review is to discuss in details some
recent insights and still-debated findings regarding the CNH
system. The activity of CNH system not only depends on the
production/secretion of CNHs by cardiomyocytes but is also
related both to the peripheral activation of circulating inac-
tive precursor of natriuretic hormones (such as proBNP) and
to the transduction of the hormone signal by specific recep-
tors. In the first part of the review, we will discuss the data
supporting the hypothesis that the production and secretion of
CNHs is the result of a complex integration among mechanical,
chemical, hemodynamic, humoral, ischemic, and inflammatory
inputs. The cross talk between endocrine function, adipose
tissue, and sex steroid hormones will be discussed more in
detail, considering the clinically relevant relationship linking
together cardiovascular risk, sex, and body fat development
and distribution. In the second part of this review, we will
discuss the recent evidence regarding the influence on the
biological effects of the CNHs exerted by both the peripheral
maturation of proBNP and the alteration in the hormone
transduction process.
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The Regulation of Gene Expression and
Production/Secretion of ANP and BNP in Cardiomyocytes
CNHs are synthesized by cardiomyocytes as prohormones
(i.e., proANP and proBNP), which are then split into two
fragments at the time of secretion: the longer fragment includes
the inactive NT peptide (i.e., NT-proANP and NT-proBNP),
whereas the shorter one (i.e., COOH-terminus fragment) rep-
resents the active hormone (i.e., ANP and BNP) (34). Studies
on structure-activity relationships have underscored the impor-
tance of the ring structure of CNHs, related to a disulfide
cysteine bridge, which is necessary for the binding to the
specific receptors. For this reason, only ANP and BNP, pre-
senting the disulfide bridge in the peptide chain, hold hormonal
activity.
Atrial cardiomyocytes store prohormones (proANP and
proBNP) in secretory granules (16, 34, 69). In particular,
human BNP is synthesized as a 134-aa precursor protein
(preproBNP) and is subsequently processed during secretion to
form the 108-aa peptide, proBNP. The propeptide hormones of
cardiac natriuretic peptides can be enzymatically cleaved by
proprotein convertases produced in the cardiomyocytes, such
as corin and furin (24, 34, 43, 49). Indeed, the precursor
proBNP is processed to form the 76-aa NT peptide (i.e.,
NT-proBNP), and then the biologically active 32-aa COOH-
terminal peptide (i.e., BNP).
Although the distension of atrial and ventricular cardiomy-
ocytes is generally considered the main mechanical stimulus
for the production/secretion of ANP and BNP (57), endothe-
lin-1, -adrenergic agonists, and angiotensin II are also pow-
erful stimulators of production and/or release of CNHs by
cardiomyocytes (34, 52, 67) (Fig. 1 and Table 1). Furthermore,
several studies reported that arginine vasopressin (97), gluco-
corticoids (21, 64, 65), thyroid hormones (4, 33), female sex
steroids (15, 60), some growth factors (27, 39), and some
cytokines (e.g., TNF-, interleukin-1, and interleukin-6) (19,
60, 90) stimulate CNH production/secretion (Table 1). On the
contrary, nitric oxide (NO) exerts a direct inhibitory effect on
the production/secretion of CNHs (37, 48, 107) (Table 1) and
also counteracts their relaxant action on cardiac vessels by
desensitizing the big conductance calcium-activated potassium
channels of vascular smooth muscle (56).
It is generally believed that ANP is predominantly produced
in the atria, whereas BNP is predominantly produced in the
ventricles (16). Indeed, the specific atrial granules of cardio-
myocytes predominantly contain proANP (67). Experimental
animal models and clinical studies in patients with cardiovas-
cular diseases have demonstrated that CNH synthesis and
secretion may be differently regulated in atrial versus ventric-
ular cardiomyocytes and probably during neonatal versus adult
life (34, 59, 67, 69). Ventricular cardiomyocytes do not usually
display secretory granules at electron microscopy in the normal
heart (44, 47), whereas granules, similar to the atrial ones, have
been observed in samples of ventricular myocardium collected
during surgery or endocardial biopsies in patients with cardiac
disease (34, 63).
According to these findings, under physiological conditions,
ventricular myocardium produces only a limited amount of
BNP; conversely, several pathophysiological mechanisms,
such as ventricular hypertrophy, inflammation, and fibrosis,
stimulate BNP production and release from ventricular cardio-
myocytes (19, 60, 69, 77, 102). Furthermore, myocardial ische-
mia and perhaps hypoxia per se can induce the synthesis/
secretion of BNP and its related peptides by ventricular cells,
even when isolated and cultured (8, 12, 33, 89, 94) (Fig. 1).
Mammalian cells respond to low oxygen with an increased
expression of several hypoxia-inducible genes. The master
regulator of this cellular adaptation to hypoxia is the hypoxia-
inducible factor, which is a heterodimeric transcription factor.
Some studies indicate that low oxygen conditions induce the
expression of hypoxia-inducible factor-1a, which in turn acti-
Fig. 1. Highly schematic representation of
brain natriuretic peptide (BNP) gene regula-
tion in the cardiomyocyte. BNP production
by cardiomyocytes may be affected by a
huge number of neurohormones, cytokines,
and survival and growth factors, as well as
by mechanical strain and hypoxia. The stim-
ulation (or inhibition) of the MAPK activity
and the transcriptor factor NF-B may play a
relevant role in many of these regulatory
pathways (according to Refs 8, 13, 19, 34,
57, 60, 67, 91, 93, and 104). As indicated,
low oxygen conditions (hypoxia) can acti-
vate both atrial natriuretic peptide and BNP
transcription throughout an alternative path-
way by inducing the expression of hypoxia-
inducible factor (HIF)-1 (Refs. 13, 104).
GPCR, G protein-coupled receptor; PKC,
protein kinase C; PI3K, posphoinositide
3-kinase; RTK, receptor of tyrosine kinase;
ACE, angiotensin-converting enzyme; ET,
endothelin.
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vates both ANP and BNP transcription (13, 104). These data
may explain the increased BNP levels observed in patients with
ischemic heart diseases and preserved ventricular function (16,
35, 69).
Studies using culture of cardiomyocytes (especially from
rodents) have demonstrated that several factors (including
calcium, catecholamines, endothelins, angiotensin II, and some
cytokines) can regulate the expression of ANP and BNP genes
throughout the same transcriptional factors, including p38
mitogen-activated protein kinase (MAPK) (19, 34, 41, 50, 52,
56, 60, 91), as indicated in Fig. 1. A still unresolved question
is the role of insulin on the regulation of production/secretion
of CNHs by cardiomyocytes. Some studies (2, 6, 18) indicated
that insulin has a potent acute anti-inflammatory effect, which
is mediated by the inhibition of transcription factor NF-B.
According to these studies (2, 6, 18), an inhibitory role of
insulin on the production/secretion of CNHs may be hypothe-
sized. However, to our knowledge, only the study by Toku-
dome et al. (92) was performed with the specific aim to
examine the direct effects of insulin on the secretion/produc-
tion of CNHs from cardiomyocytes. This study reported that
insulin increased ANP secretion and gene expression in cul-
tures of rat cardiomyocytes, whereas glucose had no effect
(92). These conflicting results suggest that further studies are
necessary to clarify the complex biochemical pathways and
molecular mechanisms responsible for CNH production in
cardiomyocytes (34).
The Cross Talk Between the Cardiac Endocrine Function
and Adipose Tissue System
Since some adipokines (such as leptin, resistin, and visfatin)
are able to activate the transcription factor NF-B (1, 55, 84,
93, 101), it may be hypothesized that these adipokines also
have a stimulatory action on ANP and BNP throughout this
metabolic pathway. However, Mascareno et al. (64) reported
that leptin has antihypertrophic action in vivo in mice, rather
than a hyperthrophic effect, as expected by the studies in the
culture of ventricular cardiomyocytes. This effect is indeed
mediated in vivo by CNHs, since leptin was found to increase
the expression of the ANP gene by the activation of nuclear
factor of activated T-cell domain of ANP gene promoter (64).
On the contrary, Yuan et al. (107) reported that intravenous
infusion of leptin reduces ANP plasma levels via an NO-
dependent mechanism in rats. Therefore, these studies point
out that CNH production/secretion by cardiomyocytes can be
differently regulated by the same biological factor (such as
leptin) throughout multiple metabolic pathways activated, or
inhibited, according to different pathophysiological conditions.
On the other hand, recent findings indicated that CNHs have
a role in the regulation of fat tissue function and growth (17)
and also exert potent lipolytic effects in human fat cells (52).
Furthermore, ANP can increase the production of adiponectin
(95), a polypeptide involved in glucose and free fatty acid
metabolism (so to be protective in diabetes and metabolic
syndrome), whereas the release of leptin is inhibited in culture
of human adipocytes (28, 68).
The above-mentioned studies indicate that there is a cross
talk between the cardiac endocrine function and adipose
tissue. From a pathophysiological point of view, further
studies on the interrelationship between CNHs and adipo-
kines may allow new insights on the link between metabolic
disorders (such as diabetes mellitus, metabolic syndrome,
and obesity), body fat distribution, and increased cardiovas-
cular risk (7, 15). Indeed, a still unexplained finding is the
lower CNH levels found in obese compared with lean health
subjects and patients with heart failure (HF) (15). Although
the increased expression of clearance natriuretic peptide
receptor (i.e., NPR-C) in fat tissue can, at least in part,
explain this finding (see Resistance to the Biological Effects
of CNHs), the increased production of some adipokines may
be a good explanation for a link relating the increased
visceral fat tissue to reduced circulating levels of CNHs. A
good candidate should be a biological substance (or more
substances) showing inhibitory properties on the produc-
tion/secretion of CNHs and released by fat tissue.
Table 1. Biological factors suggested to stimulate or inhibit the production/secretion of CNHs in vivo or in cell culture
of cardiomyocytes
Suggested Factors Suggested Mean Intracellular Signaling Mechanism References
Stimulating
Mechanical strain Transcription factor NF-B activated by p38 MAPK 57
Angiotensin II Transcription factor NF-B activated by p38 MAPK 34, 52, 67
Endothelin-1 Transcription factor NF-B activated by p38 MAPK 34, 52, 67
-Adrenergic agents Transcription factor NF-B activated by p38 MAPK 16, 34, 52, 67
Arginine vasopressin Ca2 influx and PKC 97
Cytokines (including IL-1, IL-6, TNF-) Transcription factor NF-B activated by p38 MAPK 19, 60
Growth factors (such as bFGF) MAPK 27, 39
Prostaglandins (such as PGF2 and PGD2) PLC, IP3, PKC, and MLCK pathway 5, 54
Lipolysaccharide Transcription factor NF-B activated by p38 MAPK 19
Chromogranin B Transcription factor NF-B and IP3/Ca2 influx 41
Thyroid hormones Thyroid hormone regulatory element 4, 21, 32, 65, 66, 69
Corticosteroids Glucocorticoid responsive element 21, 65, 66, 69
Estrogens Not yet determined 51, 61
Inhibiting
Androgens Not yet determined 9, 42, 76
Nitric oxide Transcription factor JMJ 37, 48, 107
CNH, cardiac natriuretic hormone; MAPK, mitogen-activated protein kinase; PKC, protein kinase C; IL, interleukin; TNF, tumor necrosis factor; bFGF, basic
fibroblastic growth factor; PG, prostaglandin; PLC, phospholipase C; IP3, inositol 1,4,5-trisphosphate; MLCK, myosin light chain kinase; JMJ, jumonji
domain-containing protein.
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The Cross Talk Between Cardiac Natriuretic and Sex
Steroid Hormones
According to the hypothesis that CNHs share complex
interactions with the neurohormonal system, the interest on the
interrelationships between cardiac endocrine and gonadal func-
tions progressively increased throughout the first 10 years of
this century. Cardiovascular risk is significantly lower in
healthy premenopausal women compared with men, a differ-
ence abolished after menopause, suggesting an important role
for female sex steroid estrogens on pathophysiological mech-
anisms related to cardiovascular diseases (15, 51). On the other
hand, CNHs exert some cardioprotective actions, including
1) decrease in blood pressure; 2) increase in natriuresis and
diuresis; and 3) inhibition of both the sympathetic nervous
system and the release or action of several hormones, including
aldosterone, angiotensin II, endothelins, renin, and vasopressin
(16). Kuroski de Bold (51) hypothesized that the lower cardio-
vascular risk of healthy fertile women compared with men is,
at least in part, due to the stimulatory effect of sex female
steroid hormones on cardiac endocrine function, in this way
virtually opening the search for some pathophysiological
mechanisms linking together sex, endocrine function, and
cardiovascular risk.
There are only few experimental studies in animal models
specifically designed to investigate the influence of sex steroid
hormones on cardiac endocrine function (15). These studies
have some important limitations: rodents rather than primates,
and castrated rather than fertile animals, have been studied. As
a consequence, the results of these studies should be applied
with extreme caution to healthy fertile men and women.
Experimental studies in animals have pointed out that female
sex steroids increase ANP gene expression in a dose-dependent
manner and that both estradiol and progesterone are necessary
to maintain suitable levels of ANP gene expression in rat
cardiomyocytes (15). Furthermore, hormone replacement ther-
apy with female steroid hormones shows a stimulatory action
on the production/secretion of CNHs in postmenopausal
women (46, 61).
As far as the effects of androgens on the production/secre-
tion of CNHs are concerned, the currently available data are
still conflicting. Results of experimental studies with atrial
cultured myocytes of newborn rats suggested that testosterone
stimulates the synthesis and secretion of both ventricular and
atrial ANP (65, 66). On the contrary, in another study, per-
formed in castrated male rats, plasma ANP concentration and
atrial stores were found to be increased and testosterone re-
placement was associated with a decrease in plasma ANP
concentration, but not in atrial stores (42). In a clinical study,
androgen receptor blockade and, to a lesser extent, androgen
suppression were found to increase NT-proBNP plasma value
in men with prostate cancer (23).
More recently, two large population-based studies have
attempted to clarify the role of male sex steroid hormones on
the regulation of cardiac endocrine function in humans. The
Dallas Heart Study, observed by Chang et al. (9), reported no
association between estrogen status and NT-proBNP levels,
whereas a strong inverse association was found between mea-
sures of free testosterone and NT-proBNP in young women
(age range, 35–49 yr). Saenger et al. (76) reported an inverse
association of NT-proBNP with serum testosterone, a direct
association with sex hormone-binding globulin, and no signif-
icant association with circulating levels of estradiol in a large
population of girls and boys (age range, from 2 mo up to 18 yr).
The above-mentioned data suggest that female and male sex
steroid hormones together contribute to the regulation of pro-
duction/secretion of CNHs: estrogens may have a stimulatory,
whereas androgens a inhibitory, action (15). The interrelation-
ships between CNHs and steroid hormones may be schemati-
cally represented by three distinct retroactive mechanisms. In
normal cycling women, natriuretic peptides may share an
inhibitory action on steroidogenesis, follicular development,
granulosa cell maturation, and ovulation, whereas estrogens
have a stimulatory effect on the production/secretion of
ANP and BNP production/secretion by cardiomyocytes.
Conversely, in adult men, natriuretic peptides may share a
stimulatory effect on testis steroidogenesis, whereas andro-
gens may have an inhibitory effect on ANP and BNP
production/secretion by cardiomyocytes. Adrenal cortico-
steroids (including glucocorticosteroids and mineralcortico-
steroids) show both direct and indirect stimulating actions
on cardiac endocrine function, whereas CNHs inhibit the
production of corticosteroids by adrenal gland both directly
throughout the specific natriuretic peptide receptors on zona
fasciculata and glomerulosa cells of adrenal gland and
indirectly by inhibiting the action of renin-angiotensin sys-
tem. However, although fascinating, this hypothesis needs
further evidence. In particular, it should be elucidated
whether sex steroids are actually able to affect (increase or
decrease) the production/secretion of BNP in mammalian
cardiomyocytes both in cell cultures and in vivo (15).
Plasma proBNP May Be a Circulating Precursor of Active
BNP Hormone
Cardiac endocrine function has attracted the attention of
clinicians when the pivotal role of CNHs in the pathophysiol-
ogy of HF was established (10, 11, 16, 36, 69). Furthermore,
the introduction of the assay of B-type-related natriuretic
peptides in clinical practice has resulted in a significant accu-
racy improvement of the diagnostic and prognostic stratifica-
tion workup in patients with cardiac diseases (14, 22, 25, 26,
29, 45, 70).
A deficient response of cardiac endocrine function was
proposed to explain the altered electrolyte and fluid homeosta-
sis occurring in chronic HF (16). This phenomenon, defined as
the “endocrine paradox” of the heart (33, 36), is characterized
by extremely high-circulating levels of hormones with power-
ful diuretic/natriuretic and vasodilator activity in patients with
congestive HF, showing signs of fluid retention and vasocon-
striction. Some recent findings suggest that the posttransla-
tional processing of ventricular proBNP is not efficient in HF
patients. As a consequence, the great part of BNPs, assayed in
these patients, is devoid of biological activity (11, 34, 58).
In addition to bioactive BNP1–32, a huge numbers of circu-
lating proBNP-derived fragments can be identified by chro-
matographic procedures in human plasma, including the intact
and glycosylated forms of precursor proBNP and NT-truncated
BNP form 3–32 (34, 43, 58, 80–83). When compared with
inactive peptides proBNP and NT-proBNP, the active peptide
BNP has a shorter plasma half-life (15–20 min vs. 1 or 2 h)
and consequently lower plasma concentration (Table 2).
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Recent studies demonstrated that the intact or glycosylated
forms of proBNP constitute a significant portion of immuno-
reactive B-type-related peptides circulating in plasma of pa-
tients with HF (34, 58, 80–83). According to these findings, it
is theoretically conceivable that the active hormone (i.e., BNP)
may be produced even in vivo from the circulating intact
precursor proBNP through enzymatic cleavage by some
plasma proteases (24, 43, 49). Indeed, a very recent study
demonstrated that the processing of human proBNP to active
BNP can occur in the circulation by means of in vivo in a rat
model (81). The above-mentioned studies (11, 34, 43, 58) open
a new and more complex scenario regarding the circulating
BNPs: the intact precursor proBNP might be actually consid-
ered a circulating prohormone. This hypothesis assumes that
the peripheral processing of circulating proBNP would be
submitted to regulatory rules, possibly altered with HF pro-
gression.
Resistance to the Biological Effects of CNHs
All natriuretic peptides share a direct diuretic, natriuretic,
and vasodilator effect as well as an inhibitory action on the
inflammatory processes of both myocardium and smooth mus-
cle cells (19, 40, 62), thus exerting a protective effect on
endothelial dysfunction and vascular remodeling (71, 79, 98).
These effects are mediated by two different guanylate cyclase-
coupled receptors, NPR-A (more specific for ANP and BNP)
and NPR-B (more specific for CNP), whereas a third specific
receptor NPR-C, not coupled to a guanylate cyclase, has
essentially a clearance function for all natriuretic peptides (16).
A blunted natriuretic response after pharmacological doses
of ANP and BNP has been observed in experimental models
and in patients with chronic HF, suggesting a resistance to the
biological effects of CNHs, principally natriuresis (10, 73,
100). As discussed in detail previously (11, 16), resistance to
the biological action of CNHs can be attributed at least to three
different causes/mechanisms, acting at prereceptor, receptor,
and postreceptor levels, respectively (Table 3).
As concerns the prereceptor level, recent studies suggest that
in patients with HF, there is an insufficient posttranslation
maturation of the biosynthetic precursors of BNP system (i.e.,
proBNP). An insufficient maturation of proBNP can be caused
by an altered processing that may occur before (i.e., within
the cardiomyocyte) or after (i.e., in the bloodstream) the
secretion of the prohormone (33, 36). Circulating proBNP
can be processed in vivo in the human blood by a soluble
form of protease corin. Indeed, corin is present in human
blood (24), and so this enzyme can process the circulating
intact precursors of natriuretic hormones (49). Furthermore,
plasma corin levels have been found to be significantly
lower in HF patients than in healthy controls with a reduc-
tion in the plasma enzyme levels paralleled by the severity
of the disease (24). An altered processing of proBNP might
represent a possible future therapeutical target, i.e., by
developing drugs able to induce the cleavage of the prohor-
mone into the active BNP. Furthermore, the measurement of
circulating corin levels may be used as a diagnostic and/or
prognostic biomarker of HF (24).
Considering the possible causes of resistance at the re-
ceptor level (Table 3), it is theoretically conceivable that an
increased expression of the NPR-C in some peripheral
tissues can increase the peripheral clearance of CNHs
throughout this specific way, thus reducing their circulating
levels. It is well known that obese individuals have reduced
levels in circulating BNP compared with lean subjects (15,
78). The finding that NPR-C is overexpressed in adipocytes
of obese individuals allowed an explanation for these re-
duced CNH levels in obese subjects (15, 78). Moreover,
some gene polymorphisms of specific natriuretic peptide
receptors have associated with some cardiovascular dis-
eases, including systemic arterial hypertension (72, 74, 96,
106), cardiomyopathy (103), and stroke (75). However, the
true clinical impact of these studies is still debated, consid-
ering that the most frequent cardiovascular diseases are
polygenic disorders (99).
Finally, at the postreceptor level, an increased activity of the
cGMP phosphodiesterase (PDE) V, which metabolizes cGMP,
may contribute to increase the resistance to the natriuretic
peptide action. The CNHs and NO systems are activated in
congestive HF, resulting in an increased synthesis of cGMP,
which serves as a second messenger for both humoral systems
(88). In severe chronic experimental HF, glomerular cGMP
accumulation decreases in response to both ANP and sodium
nitroprusside, whereas cGMP- and cGMP-PDE activities are
enhanced (88). In vivo, cGMP PDE V inhibition was reported
to markedly potentiate the natriuretic response to acute volume
expansion, an effect that was attenuated by the administration
of a monoclonal antibody directed against ANP (105). Forfia et
al. (31) demonstrated that the inhibition of PDE V by sildenafil
Table 3. Classification of possible mechanisms of resistance
to biological effects of CNH
Prereceptor level
A) Presence of inactive peptides in plasma
B) Increase in inactivation/degradation of active peptides
1) Upregulation of NPR-C
2) Increased activity of proteases
C) Decreased renal filtration
Receptor level
A) Downregulation of NPR-A and NPR-B in target tissues
B) Altered CNH receptor binding or desensitization
Postreceptor level (activated counterregulatory mechanisms)
Altered intracellular signaling
1) Decreased cGMP cellular accumulation (decreased production or
increased degradation)
2) Altered intracellular pathways downstream cGMP
NPR-A, NPR-B, and NPR-C, natriuretic peptide receptor typres A, B, and
C, respectively.
Table 2. Biochemical and physiological characteristics of
BNP, NT-proBNP, and proBNP peptides
BNP NT-proBNP proBNP
Molecular
mass, Da 3,462 8,457* 11,900*
Amino acids 32 76 108
Biological
function active hormone inactive prohormone
Half-life, min 15–20 60 60
Glycosylation not glycosylated Highly glycosylated
in vivo
Highly glycosylated
in vivo
*Molecular mass of NH2-terminal (NT)-pro-brain natriuretic peptide
(proBNP) and proBNP depends on the degree of glycosylation of the peptide.
Reported are the molecular masses of nonglycosylated peptides.
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had minimal effects on cardiovascular hemodynamics in
healthy dogs; conversely, when sildenafil was administered to
HF animals, it exerted similar hemodynamic effects as syn-
thetic BNP, and the combination of BNP and sildenafil was
additive in reducing pulmonary pressures. These findings dem-
onstrated that an increased PDE V activity is involved in the
pathophysiology of HF, suggesting a novel possible pharma-
cological target.
Conclusions and Prospective Remarks
A huge number of experimental and clinical studies,
published in the first decade of this century, have added
further support to the hypothesis that that human heart is a
relevant component of a complex network including endo-
crine, nervous, and immune systems. In particular, novel
research fields have been intensively developed with the aim
to elucidate the complex interrelationships between cardiac
endocrine function, sex steroid hormones, and adipokine
systems (15). However, some issues need to be further
investigated.
Although fascinating, the hypothesis that gonadal function
regulates both body fat distribution and cardiac endocrine
function needs further evidence (15). In particular, it is still
lacking the conclusive demonstration that sex steroids (espe-
cially androgens) are able to actually affect (increase or de-
crease) the production/secretion of CNHs from mammalian
(including human) cardiomyocytes both in cell cultures and in
vivo.
Obesity is associated with ectopic lipid deposition even in
the heart, which may directly exert a lipotoxic effect on the
myocardium by locally secreting several cytokines and adipo-
kines (38). These substances may affect both the endocrine and
the contractile function of the cardiomyocytes through a para-
crine effect (38). However, the specific role of adipokines in
the CNH production/secretion process needs to be further
investigated.
These studies will hopefully shed light on the complex, but
clinically relevant, interrelationships between cardiovascular
risk, sex, and body fat mass and distribution (7, 15, 51).
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